OpenNashEarnings

Cardinal Health (CAH) · Health Care

Cardinal Health Q1 FY2027 earnings: summary, key numbers & outlook

Results filed 5 Nov 2026 · Quarter ended 30 Sep 2026

Slides (23 pages)Official transcript (PDF) ↗Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Cardinal Health raised its fiscal 2027 outlook as brand and specialty pharma demand grew, a CVS Health distribution renewal was signed and a diabetes supplies acquisition was lined up.

Cardinal's pharmaceutical distribution business grew on brand and specialty drug sales from existing customers, helped by a better generics program. Its home-health, nuclear and logistics businesses (reported together as Other) grew across all three units. Medical products were flat: Cardinal Health Brand grew, but distribution and currency effects weighed. The company closed the Strive Medical acquisition, a multi-specialty supply provider focused on urology.

Management is leaning further into specialty, supporting community-based physicians with data, platform and distribution services, while continuing its Global Medical Products and Distribution improvement plan. Near-term deals include a binding letter of intent to renew CVS Health distribution agreements and the AdaptHealth Diabetes Health acquisition, expected in Q3. The main risks are branded drug pricing regulation, tariffs, the Iran conflict, generic deflation and Department of Justice investigations.

Slides & documents

Open the slide deck (PDF, 23 pages) ↗

Cardinal Health Q1 FY2027 slide deck, page 1Cardinal Health Q1 FY2027 slide deck, page 2Cardinal Health Q1 FY2027 slide deck, page 3Cardinal Health Q1 FY2027 slide deck, page 4Cardinal Health Q1 FY2027 slide deck, page 5Cardinal Health Q1 FY2027 slide deck, page 6

Showing the first 6 of 23 pages.

From Cardinal Health investor relations

SEC filing

Key numbers

Revenue · GAAP
$67.5 billion

up 5% from a year ago

Operating earnings · GAAP
$753 million

up 13% from a year ago

Diluted EPS · GAAP
$2.38

up 27% from a year ago

Non-GAAP diluted EPS · non-GAAP
$3.26

up 28% from a year ago

Operating cash flow · GAAP
$1.4B

up from $973 million a year ago

Non-GAAP adjusted free cash flow · non-GAAP
$1.6B

up from $1,285 million a year ago

Segment or metricValueChange
Pharmaceutical and Specialty Solutions revenue$62.6 billionup 6%
Pharmaceutical and Specialty Solutions segment profit$783 millionup 17%
Global Medical Products and Distribution revenue$3.2 billionapproximately flat
Global Medical Products and Distribution segment profit$33 milliondown 28%
Other revenue$1.8 billionup 7%
Other segment profit$193 millionup 16%
Where each number comes from
  • Revenue: “today reported first quarter fiscal year 2027 revenues of $67.5 billion, an increase of 5% from the first quarter of fiscal year 2026”
  • Operating earnings: “First quarter GAAP operating earnings increased 13% to $753 million and GAAP diluted earnings per share (EPS) increased 27% to $2.38.”
  • Diluted EPS: “First quarter GAAP operating earnings increased 13% to $753 million and GAAP diluted earnings per share (EPS) increased 27% to $2.38.”
  • Non-GAAP diluted EPS: “Non-GAAP diluted EPS increased 28% to $3.26, reflecting the increase in non-GAAP operating earnings, a lower share count, and a lower effective tax rate.”
  • Operating cash flow: “Net cash provided by operating activities | 1,398 | 973 Cash flows from investing activities: Acquisition of subsidiaries, net of cash acquired | (149) | (41)”
  • Non-GAAP adjusted free cash flow: “Non-GAAP adjusted free cash flow | $1,583 | $1,285 For more information on these measures, refer to the Use of Non-GAAP Measures and Definitions schedules.”
  • Pharmaceutical and Specialty Solutions revenue: “First quarter revenue for the Pharmaceutical and Specialty Solutions segment increased 6% to $62.6 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.”
  • Pharmaceutical and Specialty Solutions segment profit: “Pharmaceutical and Specialty Solutions segment profit increased 17% to $783 million in the first quarter, primarily driven by contributions from brand and specialty products”
  • Global Medical Products and Distribution revenue: “First quarter revenue for the Global Medical Products and Distribution segment was approximately flat to the prior year at $3.2 billion.”
  • Global Medical Products and Distribution segment profit: “Global Medical Products and Distribution segment profit decreased to $33 million in the first quarter, due to unfavorable distribution and foreign exchange impacts”
  • Other revenue: “First quarter revenue for Other increased 7% to $1.8 billion, driven by growth across the three operating segments: Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.”
  • Other segment profit: “Other profit increased 16% to $193 million in the first quarter, driven by growth across the three operating segments: OptiFreight Logistics, Nuclear and Precision Health Solutions”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ1 FY2027vs year agovs last quarter
Revenue$67.5B+5.5%—
Operating income$753.0M+12.7%—
Net income$554.0M+23.1%—
Diluted EPS$2.38+26.6%—
Free cash flow$1.2B+43.5%—
Gross margin3.8%+0.2 pts—
Operating margin1.1%+0.1 pts—

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Non-GAAP diluted EPSfiscal year 2027$12.80 to $13.00
Non-GAAP effective tax ratefiscal year 202718.5% to 19.5%
Pharmaceutical and Specialty Solutions profit growthfiscal year 202710% to 12%
Other profit growthfiscal year 202717% to 20%
Other revenue growthfiscal year 202712% to 14%
Capital expendituresfiscal year 2027~$700M
Non-GAAP adjusted free cash flowfiscal year 2027$3.5B – $4.0B

Key takeaways

  1. CVS Health distribution agreements set for renewal

    Cardinal signed a binding letter of intent to renew its pharmaceutical distribution agreements with CVS Health. This secures a long-standing relationship and enables continued volume growth in the largest segment.

  2. Brand and specialty drugs drive pharma growth

    Pharmaceutical and Specialty Solutions grew on brand and specialty sales from existing customers, plus positive generics program performance. Management raised the segment's profit growth outlook to 10% to 12%.

  3. Specialty strategy centers on community physicians

    Cardinal positions itself to support community-based physicians through MSO platforms, data and technology solutions, scaled contracting and distribution. Its slides cite approximately 60% of the multi-specialty and approximately 40% of the oncology market for platforms.

  4. Acquisitions broaden supply and home-health reach

    Cardinal closed Strive Medical, a multi-specialty supply provider focused on urology, and expects to close AdaptHealth's Diabetes Health business in Q3 of fiscal 2027. Both extend its supply and at-home offerings.

  5. Medical products still lag despite brand growth

    Global Medical Products and Distribution revenue was flat as Cardinal Health Brand growth was offset by lower distribution revenue. Management continues executing its improvement plan, with unfavorable distribution and foreign exchange hurting profit.

Charts

Revenue$67.5B+5.5% y/yQ1 FY27
Q4 FY24: $59.9B (worked out from the annual figure)Q4 24$59.9BQ1 FY25: $52.3BQ1 25$52.3BQ2 FY25: $55.3BQ2 25$55.3BQ3 FY25: $54.9BQ3 25$54.9BQ4 FY25: $60.2B (worked out from the annual figure)Q4 25$60.2BQ1 FY26: $64.0BQ1 26$64.0BQ2 FY26: $65.6BQ2 26$65.6BQ1 FY27: $67.5BQ1 27$67.5B

Fourth quarter worked out from the annual figure.

Data
Q4 FY24$59.9B *
Q1 FY25$52.3B
Q2 FY25$55.3B
Q3 FY25$54.9B
Q4 FY25$60.2B *
Q1 FY26$64.0B
Q2 FY26$65.6B
Q1 FY27$67.5B
Diluted EPS (GAAP)$2.38+26.6% y/yQ1 FY27
Q1 FY25: $1.70Q1 25$1.70Q1 FY26: $1.88Q1 26$1.88Q1 FY27: $2.38Q1 27$2.38
Data
Q1 FY25$1.70
Q1 FY26$1.88
Q1 FY27$2.38

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin1.1%+0.1 pts y/yQ1 FY27
Q4 FY24: 0.7%Q4 240.7%Q1 FY25: 1.1%Q1 251.1%Q2 FY25: 1.0%Q2 251.0%Q3 FY25: 1.3%Q3 251.3%Q4 FY25: 0.7%Q4 250.7%Q1 FY26: 1.0%Q1 261.0%Q2 FY26: 1.1%Q2 261.1%Q1 FY27: 1.1%Q1 271.1%
Data
Q4 FY240.7%
Q1 FY251.1%
Q2 FY251.0%
Q3 FY251.3%
Q4 FY250.7%
Q1 FY261.0%
Q2 FY261.1%
Q1 FY271.1%
Free cash flow$1.2B+43.5% y/yQ1 FY27
Q4 FY24: $1.9BQ4 24$1.9BQ1 FY25: -$1.7BQ1 25-$1.7BQ2 FY25: -$495.0MQ2 25-$495.0MQ3 FY25: $2.8BQ3 25$2.8BQ4 FY25: $1.3BQ4 25$1.3BQ1 FY26: $865.0MQ1 26$865.0MQ2 FY26: $555.0MQ2 26$555.0MQ1 FY27: $1.2BQ1 27$1.2B
Data
Q4 FY24$1.9B
Q1 FY25-$1.7B
Q2 FY25-$495.0M
Q3 FY25$2.8B
Q4 FY25$1.3B
Q1 FY26$865.0M
Q2 FY26$555.0M
Q1 FY27$1.2B

Operating cash flow minus capital expenditure, from cash flow statements.

Questions

What drove growth in Cardinal Health's pharmaceutical segment?

Brand and specialty pharmaceutical sales growth from existing customers drove revenue, while brand and specialty products and positive generics program performance drove profit.

What is happening with CVS Health?

Cardinal entered a binding letter of intent to renew its pharmaceutical distribution agreements with CVS Health, enabling continued volume growth in the Pharmaceutical and Specialty Solutions segment.

Which acquisitions is Cardinal Health making?

It closed Strive Medical, a multi-specialty supply provider focused on urology, and expects to complete the purchase of AdaptHealth's Diabetes Health business in Q3 of fiscal 2027.

How is Cardinal pursuing specialty and physician-practice strategy?

It is supporting community-based physicians with MSO platforms, analytics and real-world evidence, distribution and GPO offerings. It launched the INSIGHT-IBD real-world evidence study with Eli Lilly.

What are the main risks to Cardinal's plan?

Management cites branded drug pricing regulation, tariffs, the Iran conflict, generic deflation, and Department of Justice investigations under the Anti-Kickback Statute and False Claims Act.

Call recording

Call recording on YouTube ↗. Official replay ↗.

Read Cardinal Health's official transcript ↗.